GCC 1490: Prospective Patient Registry for Radiation Oncology Techniques and Quality

Sponsor
University of Maryland, Baltimore (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02368106
Collaborator
(none)
0
1
154
0

Study Details

Study Description

Brief Summary

This study will create a patient data registry to collect and analyze information on technology usage and outcomes among patients receiving a broad range of relatively new radiation treatments that have become standards of care in our practice. Review of this information will serve as a basis for development of better patient management plans, to inform decisions about acquisition of new technologies, to provide information about quality in our care delivery, and to create a database that will securely warehouse ongoing information about what treatments the patients we serve need most and the challenges they face in the treatment process. The information gathered is likely to not only improve our services at the University of Maryland and its community sites but to advance medical science and enhance the quality of care for cancer patients.

Condition or Disease Intervention/Treatment Phase
  • Radiation: Radiation Therapy

Detailed Description

The purpose of this study is to create a robust and long-term patient data registry containing limited demographic, diagnostic, treatment, and follow-up data on patients at the study sites undergoing one or more of the following radiation treatments/technologies:

Brachytherapy, including High-Dose-Rate and Low-Dose-Rate Techniques/ GammaPod Therapy/ GRID Treatment/ Image-Guided Radiation Therapy/ Intensity-Modulated Radiation Therapy and Intensity-Modulated Arc Therapy/ MammoSite and SAVI Applicator/ Photodynamic Therapy/ Proton Therapy/ SIR Spheres and Radiolabeled Microsphere Therapy/ Stereotactic Radiosurgery and Stereotactic Body Radiotherapy/ Thermal Therapy (Hyperthermia)

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
0 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Patient Registry for Prospective Research on Evolving Radiation Oncology Techniques and Quality
Anticipated Study Start Date :
Feb 1, 2018
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Dec 1, 2030

Arms and Interventions

Arm Intervention/Treatment
Radiation Therapy

Participants receiving one of the 11 listed therapy modalities.

Radiation: Radiation Therapy
targeted radiation treatment

Outcome Measures

Primary Outcome Measures

  1. Numbers of patients experiencing toxicities/adverse events both during and at follow-up after radiation therapy with any of 11 therapeutic modalities. [5 years]

    Records will be assessed to identify per-patient numbers and grades of toxicities and adverse events resulting from radiation treatment for oncologic conditions as graded by treating physicians according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) during the period of radiation treatment and at each regularly scheduled clinical follow-up appointment, for each of the 11 therapeutic modalities listed as interventions.

Secondary Outcome Measures

  1. Numbers of patients with different initial diagnoses associated with short- and long-term toxicities with specific radiation treatments. [5 years]

    Records will be assessed to identify numbers of patients with specific initial diagnoses (from approximately 100 International Statistical Classification of Diseases and Related Health Problems [ICD 9] malignant neoplasm diagnoses) who experience short- and long-term toxicities after any of the 11 therapeutic modalities listed as interventions.

  2. Numbers of men and women who experience short- and long-term toxicities after specific radiation treatments. [5 years]

    Records will be assessed to identify numbers of men and women who experience CTCAE-defined levels of toxicity during and after radiation treatment with any of the 11 therapeutic modalities listed as interventions.

  3. Age differences in short- and long-term toxicities associated with specific radiation treatment modalities. [5 years]

    Records will be assessed to identify numbers of men and women between the ages of 18-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, and ≥90 years who experience CTCAE-defined levels of toxicity during and after radiation treatment with any of the 11 therapeutic modalities listed as interventions.

  4. Patient income differences in short- and long-term toxicities associated with specific radiation treatment modalities. [5 years]

    Records will be assessed for income (by patient home zip code per U.S. Internal Revenue statistics available at http://www.irs.gov/uac/SOI-Tax-Stats-Individual-Income-Tax-Statistics-ZIP-Code-Data-(SOI)) to identify income level differences and per-patient numbers/ types of CTCAE-defined levels of toxicity during and after radiation treatment with any of the 11 therapeutic modalities listed as interventions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients who are 18 years old or older and scheduled to undergo any of the listed radiation treatment technologies at the University of Maryland Medical Center or one of its community sites as included in this protocol provided s/he consents to participate.
Exclusion Criteria:
  • Patients who are incarcerated or in legal custody are not eligible for this study.

  • Patients who are younger than 18 years, are cognitively impaired, or are otherwise unable to provide informed consent.

  • Patients who are pregnant

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ummc Msgcc Baltimore Maryland United States 21201

Sponsors and Collaborators

  • University of Maryland, Baltimore

Investigators

  • Principal Investigator: William Regine, MD, UMMC MSGCC Department of Radiation Oncology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Department of Radiation Oncology, Principle Investigator, University of Maryland, Baltimore
ClinicalTrials.gov Identifier:
NCT02368106
Other Study ID Numbers:
  • HP-00060494
First Posted:
Feb 20, 2015
Last Update Posted:
Sep 12, 2019
Last Verified:
Sep 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Department of Radiation Oncology, Principle Investigator, University of Maryland, Baltimore
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 12, 2019